GET DAILY SIGNALSBiodesix (BDSX): $33 Analyst Target Suggests +229% Upside After Recent Reset
Key Takeaways
- The central target of $33 is the arithmetic mean of five current analyst price targets, which range from $30 to $35.
- The latest verified close was $10.02 (November 10, 2026), so reaching $33 would require upside of roughly 229%.
- Analysts maintained Buy-equivalent ratings after the Q3 report but trimmed several targets to reflect reduced 2026 guidance.
- Key supports include double-digit diagnostic testing growth, an 81% gross margin, and a planned path to profitability by late 2027.
- The biggest risks are a recent revenue miss, a cut to full-year guidance, sales-force turnover, and ongoing cash consumption.
- For more context, see Major News, Today's Price Move, the Forecast, and Earnings pages.
Analyst Price Targets and Consensus View
Biodesix, Inc. (BDSX) is a Colorado-based diagnostic solutions company focused on blood-based lung tests, including the Nodify Lung and IQLung test families. Following its November 5, 2026 third-quarter report, five current analyst price targets were reviewed: H.C. Wainwright (Yi Chen) at $34, Canaccord Genuity at $35, TD Cowen at $34, Roth MKM at $30, and Lake Street at $30. That produces a mean of approximately $32.60, rounded to a central target of $33, with a range of $30 to $35.
Although every firm kept a Buy-equivalent rating, several cut their targets after the quarter: H.C. Wainwright lowered to $34 from $38, TD Cowen to $34 from $40, and Lake Street to $30 from $40. The revisions reflect reduced 2026 revenue guidance rather than a change in the fundamental long-term thesis, which centers on growing adoption of Nodify testing and a move toward profitability expected around the end of 2027. The tight $30-to-$35 band indicates broad agreement on valuation even as the stock trades far below those levels. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
BDSX closed at $10.02 on November 10, 2026, after falling roughly 57% on November 6 in response to third-quarter results. Reaching $33 would require a move of about 229%, which is a very large required advance. The shares traded as high as $31.97 within the past 52 weeks and now sit near the lower portion of a $5.26-to-$31.97 range.
The path back toward the target depends primarily on rebuilding commercial capacity. Management attributed the Q3 shortfall to averaging only 101 sales representatives against expectations, higher-than-expected primary-care seasonality, and customer-delayed development services projects. It framed these as execution and timing issues rather than a demand problem, noting that diagnostic testing revenue still grew 16% year over year on roughly 24% test-volume growth.
What Could Support a Move Toward the Target
- Diagnostic testing revenue of about $23.0 million grew 16% year over year, with test volumes up 24%.
- Gross margin held at approximately 81%, consistent with six consecutive quarters above 80%.
- Management reported that October marked the strongest month of new physician acquisition in 2026, and sales-representative headcount was rebuilding toward roughly 115 by year-end.
- The company is advancing a complementary minimal residual disease (MRD) program and a radiomic nodule test targeted for commercialization in 2028.
- Analyst ratings remain Buy-equivalent, signaling confidence in the long-term growth and profitability narrative.
What Could Prevent the Target From Being Reached
- Third-quarter revenue of $24.0 million missed estimates, and full-year 2026 guidance was cut to $101-$103 million from $108-$114 million.
- Sales-representative turnover limited new-physician acquisition, a core driver of test-volume growth.
- Development services revenue fell to about $1.0 million from $1.9 million a year earlier, with some projects pushed into 2027.
- The company remains unprofitable, with a net loss of roughly $8.0 million in Q3 and cash of about $28.4 million, requiring disciplined spending to reach its profitability goal.
- As a micro-cap diagnostics company with a market capitalization near $111 million, the shares are exposed to execution and liquidity risk.
Technical Levels and Market Structure
The post-earnings decline reset the technical picture. The prior high of $31.97 from late September 2026 now acts as a distant resistance reference, while the November low near $8.53 provides a key support zone after the initial sell-off. The 50-day moving average was well above the current price, reflecting the sharp breakdown, and the 52-week low of $5.26 is a deeper support level. A sustained recovery toward $33 would require the stock to first reclaim higher levels that are currently far above the prevailing price. From what I see, monitoring these levels closely will be important in the coming weeks.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual assumptions vary. Investors should watch sales-representative hiring and retention, quarterly test-volume trends, gross-margin stability, development services project timing, and any updates to 2027 profitability guidance. Upcoming milestones include the next earnings report, analyst target revisions, and clinical data presentations such as the company's MRD strategy showcased at the Association for Molecular Pathology annual meeting.
AI Daily Buy/Sell Signals
In my experience following names like this, Tickeron's AI Daily Buy/Sell Signals provide a useful way to track shifting technical and market conditions across thousands of stocks. These signals draw on AI analysis to highlight potential Buy, Sell, or Hold points, which can help add structure when evaluating volatile opportunities without replacing independent research.
Final Assessment
The central target of $33 reflects the average of five current analyst price targets ranging from $30 to $35. From a $10.02 close, reaching it would require a very large advance of roughly 229%. The bull case rests on durable test-volume growth, strong gross margins, and a credible path to profitability, while the bear case emphasizes the recent revenue miss, reduced guidance, and sales-force turnover that triggered the sharp decline. The analyst targets were maintained after the reset but were not raised, and they remain far above the traded price. Whether the gap narrows will depend on whether management can demonstrate that the Q3 shortfall was a timing issue rather than a durable growth problem.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for BDSX turns negative, indicating new downward trend
BDSX saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 79 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
BDSX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BDSX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BDSX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDSX advanced for three days, in 202 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
BDSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.843) is normal, around the industry mean (67.298). P/E Ratio (-2.752) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.463) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. BDSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement